{"entity":{"id":"nct06035497","kind":"trial","name":"A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)","aka":["GOLSEEK-3"],"tldr":"A phase 1/2 trial of BMS-986369 in peripheral T-cell lymphomas, run by Bristol-Myers Squibb, active and no longer recruiting.","summary":"A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) is a phase 1/2 interventional study registered as NCT06035497 by Bristol-Myers Squibb, with 85 participants enrolled, started 2023-11-20 and due to reach its primary completion in 2027-01-30. Interventions recorded: BMS-986369.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06035497","url":"https://clinicaltrials.gov/study/NCT06035497"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["peripheral-t-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06035497","phase":"1/2","setting":"A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)","sponsor":"Bristol-Myers Squibb","participation":[{"nct":"NCT06035497","source":"https://clinicaltrials.gov/study/NCT06035497","fetchedAt":"2026-10-07T16:54:07.437Z","studySha256":"49de19fbe1911dca461185363f88ca048c7e1b45a321ccd122d37d2de8a7b27e","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-10-07","leadSponsor":"Bristol-Myers Squibb","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":83,"enrolmentType":"ESTIMATED","siteCount":40,"recruitingSiteCount":0,"countries":["Japan"]}],"started":"2023-11-20","startedType":"actual","enrolled":85,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06035497/","neighbours":{"cancer":[{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}